• Osteopore secures EU MDR approval for custom orthopaedic and cranial implants
• Approval unlocks new revenue streams in Europe for custom and off-the-shelf implants
• Regulatory clearance strengthens Osteopore's positioning in the European market

Australian-Singaporean regenerative medicine company Osteopore Limited (ASX: OSX) has secured market approvals for its custom orthopaedic and cranial implants in Europe. The company has obtained European Union Medical Device Regulation (EU MDR) approval for its custom orthopaedic and cranial implants, complementing its previously approved off-the-shelf neurosurgical and craniofacial implants. This regulatory clearance validates Osteopore's orthopaedic and cranial products in Europe, strengthening the company's positioning in the market. The EU MDR approval unlocks opportunities for Osteopore to offer high-value, custom implants to Europe, in addition to its off-the-shelf implants, introducing new revenue streams. Osteopore's exclusive distribution agreement with Zimmer Biomet, coupled with the EU MDR clearance, positions the company to supply customized orthopaedic and cranial implants to the European market. The European custom orthopaedic implant market is expected to grow at a CAGR of 3.3% by 2029, reaching US$15.96 billion, driven by an aging population and rising demand for advanced orthopaedic devices. The European custom cranial implant market is projected to grow at a CAGR of 9.4% by 2030, reaching US$368.7 million, primarily due to the increased prevalence of cranial surgeries.

Osteopore can now boost the reach of its orthopaedic and cranial implants in Europe, leveraging the EU MDR approval and its exclusive distribution agreement with Zimmer Biomet.